Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab

Bibliography

• Senger DR, Galli SJ, Dvorak AM, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5
   PubMed Web of Science ®Google Scholar
• Malecaze F, Clamens S, Simorre-Pinatel V, Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-82
   PubMed Web of Science ®Google Scholar
• Adamis AP, Miller JW, Bernal MT, Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Conner SJ, Humanization of an anti-vascular endothelial growth facor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70
   PubMed Web of Science ®Google Scholar
• Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 1996;12:181-220
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
   PubMed Web of Science ®Google Scholar
• Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009;24:113-21
   PubMed Web of Science ®Google Scholar
• Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009;24:113-21
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Houch K, The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64
   PubMedGoogle Scholar
• Cilley JC, Barfi K, Benson AB III, Mulcahy MF. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2007;7:739-49
   PubMed Web of Science ®Google Scholar
• Lowe J, Araujo J, Yang J, Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85:425-30
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-44
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33
   PubMed Web of Science ®Google Scholar
• Mordenti J, Thomsen K, Licko V, Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 1999;52:101-6
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9
   PubMed Web of Science ®Google Scholar
• Schmucker C, Loke YK, Ehlken C, Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011;95:308-17
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Miller JW, Gragoudas ES, Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996;114:964-70
   PubMed Web of Science ®Google Scholar
• Aiello LP, Pierce EA, Foley ED, Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT, Tolentino MJ, Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71
   PubMed Web of Science ®Google Scholar
• Robinson GS, Pierce EA, Rook SL, Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851-6
   PubMed Web of Science ®Google Scholar
• Ozaki H, Seo MS, Ozaki K, Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari MA, Adamis AP, Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46
   PubMed Web of Science ®Google Scholar
• Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006;26:354-6
   PubMed Web of Science ®Google Scholar
• Iliev ME, Domig D, Wolf-Schnurrbursch U, Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-6
   PubMed Web of Science ®Google Scholar
• Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-8
   PubMed Web of Science ®Google Scholar
• Grisanti S, Biester S, Peters S, Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-60
   PubMed Web of Science ®Google Scholar
• Gheith ME, Siam GA, de Barros DS, Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007;23:487-91
   PubMed Web of Science ®Google Scholar
• Chalam KV, Gupta SK, Grover S, Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008;18:255-62
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Oshima Y, Sakaguchi H, Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571-80
   PubMed Web of Science ®Google Scholar
• Ehlers JP, Spirn MJ, Lam A, Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28:696-702
   PubMed Web of Science ®Google Scholar
• Dunavoelgyi R, Zehetmayer M, Simader C, Schmidt-Erfurth U. Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. Clin Experiment Ophthalmol 2007;35:878-80
   PubMed Web of Science ®Google Scholar
• Caujolle JP, Maschi C, Freton A, Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumabinjection: preliminary results. Ophthalmic Res 2012;47:57-60
   PubMed Web of Science ®Google Scholar
• Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005;438:960-6
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Muragaki Y, Ooshima A. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity. Arch Dermatol Res 2005;297:161-9
   PubMed Web of Science ®Google Scholar
• Wu WS, Wang FS, Yang KD, Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol 2006;126:1264-71
   PubMed Web of Science ®Google Scholar
• Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987;32:149-70
   PubMed Web of Science ®Google Scholar
• Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994;58:439-51
   PubMed Web of Science ®Google Scholar
• Li Z, Van Bergen T, Van de Veire S, Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009;50:5217-25
   PubMed Web of Science ®Google Scholar
• O’Neill EC, Qin Q, Van Bergen NJ, Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2010;51:6524-32
   PubMed Web of Science ®Google Scholar
• Memarzadeh F, Varma R, Lin LT, Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009;50:3233-7
   PubMed Web of Science ®Google Scholar
• How A, Chua JL, Charlton A, Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2010;51:928-32
   PubMed Web of Science ®Google Scholar
• Vasudevan SK. Anti-VEGF anti-fibrosis - a comparison of ranibizumab and bevacizumab in vitro. Invest Ophthalmol Vis Sci 2009;50:E-Abstract 466
   Web of Science ®Google Scholar
• Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008;115:2141-5; e2
   PubMed Web of Science ®Google Scholar
• Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol 2012;153:352-7; e1
   PubMed Web of Science ®Google Scholar
• Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol 2010;150:399-403; e1
   PubMed Web of Science ®Google Scholar
• Bochmann F, Kaufmann C, Becht CN, ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - study Protocol. BMC Ophthalmol 2011;11:1
   PubMed Web of Science ®Google Scholar
• Coote MA, Ruddle JB, Qin Q, Crowston JG. Vascular changes after intra-bleb injection of bevacizumab. J Glaucoma 2008;17:517-18
   PubMed Web of Science ®Google Scholar
• Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006;37:148-50
   PubMed Web of Science ®Google Scholar
• Purcell JM, Teng CC, Tello C, Effect of needle bleb revision with ranibizumab as a primary intervention in a failing bleb following trabeculectomy. Invest Ophthalmol Vis Sci 2008;49:E-Abstract 4165
   Google Scholar
• CATT Research Group. Martin DF, Maguire MG, Ying GS, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
   PubMed Web of Science ®Google Scholar